Saisheng Pharmaceutical

Saisheng Pharmaceutical was established in 1999, and in 2011, it underwent an overall restructuring to establish Beijing Saisheng Pharmaceutical Co., Ltd. On June 26, 2015, it was successfully listed (stock code: 300485) with a registered capital of 484.166 million RMB. The company is located at No. 8 Xingsheng Street, Beijing Economic-Technological Development Area, Beijing.
The company's main business is the research, development, production, and sales of injection preparations. The leading products are biopharmaceuticals and biochemical drugs, covering three major therapeutic areas: cardiovascular and cerebrovascular diseases, immune diseases (anti-tumor), and neurological diseases. The company and its subsidiaries have obtained 185 drug approvals, 3 national new drug product certificates, and 2 national key new product certificates, and are the drafting units for national standards of multiple drugs. After nearly twenty years of development, the company's main products have established a good product image and market position in their respective therapeutic fields.
The company has two holding subsidiaries and one marketing center, with a product sales network across the country, and the safety and effectiveness of its products have been widely recognized by the market. Corporate culture core concept: Saisheng Pharmaceutical, caring for health. Values: persistence, innovation, responsibility, gratitude. Code of conduct: honesty and trustworthiness, unity and cooperation, positivity, rigor and responsibility.